31,538 Shares in Hims & Hers Health, Inc. $HIMS Acquired by Havemeyer Place LP

Havemeyer Place LP bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 31,538 shares of the company’s stock, valued at approximately $1,024,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Farallon Capital Management LLC increased its position in shares of Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares in the last quarter. BIT Capital GmbH increased its position in shares of Hims & Hers Health by 73.8% in the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after acquiring an additional 938,728 shares in the last quarter. SG Americas Securities LLC grew its position in Hims & Hers Health by 25.6% during the fourth quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock valued at $12,064,000 after purchasing an additional 75,679 shares in the last quarter. Vanguard Group Inc. grew its position in Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares in the last quarter. Finally, Candriam S.C.A. grew its position in Hims & Hers Health by 245.0% during the third quarter. Candriam S.C.A. now owns 306,273 shares of the company’s stock valued at $17,372,000 after purchasing an additional 217,493 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Performance

HIMS stock opened at $26.25 on Monday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $6.08 billion, a price-to-earnings ratio of -291.71, a P/E/G ratio of 49.14 and a beta of 2.37. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The firm has a 50 day moving average of $24.61 and a two-hundred day moving average of $27.02.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business’s revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.20 earnings per share. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.04 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on HIMS shares. Leerink Partners boosted their price objective on shares of Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research report on Monday, March 16th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Barclays boosted their price objective on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. Finally, Citigroup boosted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $28.70.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, Director David B. Wells bought 48,400 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was bought at an average cost of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the transaction, the director directly owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. The trade was a 27.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 7,950 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $23.64, for a total transaction of $187,938.00. Following the completion of the sale, the chief financial officer directly owned 262,954 shares of the company’s stock, valued at $6,216,232.56. This represents a 2.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 212,807 shares of company stock valued at $5,473,644. 11.76% of the stock is currently owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.